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Although the ESUR- and ACR-guidelines on contrast media recommend continuing breast-
feeding following the application of an iodinated contrast medium (ICM) [1, 2], in clinical 
routine it is questionable what to advise a lactating woman. Therefore, we analysed the 
literature dealing with this subject, and present herein the surprising result. 
 
We found eight publications dealing with ICM concentrations in breast milk (table 1) [3-10]. 
The most recent publication is 25 years old, and the others are much older (mean 39.9 
years, range 25 – 64 years). The papers present breast-milk analyses following the 









and metrizamide). Most of the analysed ICMs (metrizoate, iodamide, metrizamide, and 
iopanoic acid) have been discontinued (table 1).    
The total number of patients investigated in six papers [5-10] was only twenty-two. Following 
the subtraction of patients receiving compounds that are no longer on the market, a group of 
seven patients remains (four received iohexol, and three amidotrizoate) as basis for the 
guidelines [1, 2].  
The methods used to detect ICM in human breast milk range from titration with sodium 
thiosulphate, to spectrophotometry, UV-spectrometry, Technicon Analyzer and high pressure 
liquid chromatography (HPLC) (table 1). While older papers detected iodine [6, 7, 9, 10], 
others directly determined the ICM-molecules and their concentration in the human milk [5, 
8].  
 
The obtained results (peak values as well as iodine concentrations) vary in wide ranges 
(table 1). Peak values of iodine/ICM excreted in breast milk were measured at 0.75h up to 
60h following ICM-application (table 1). Since most of the authors did not perform continuous 
detections in human breast milk, the real peaks are unknown, so far. The same is true for the 
iodine- / ICM-concentration in breast milk. Only Ilett et al. [8] analysed the total milk volume 
excreted in 24h. The other authors measured the iodine- /ICM-concentration in a few distinct 
samples following ICM-application for contrast-enhanced image-guided procedures [5, 9, 10]. 
Consequently, we interpolated the missing values, and calculated the iodine content in 24h 
human breast milk (table 1). Thereby, the amounts of detected iodine in breast milk range 
from 0 mg/24h to 36.5 mg/24h. Possible reasons for these different results may be that the 
investigated patient group was too small, the use of different analytical methods, and 
different sampling times following ICM-application [3-10]. 
Obviously, lactating women seem to belong to different excretion types, namely low, medium 
and high [5, 9]. Studies in greater patient groups are warranted to confirm this assumption, 
and to present reliable data of ICM-concentrations in human breast milk. Currently, we do not 









statement “less than 1% of the ICM-dose applied to the mother is excreted with the breast 
milk”, could be correct or another myth [11].  
Interestingly, the two papers, which report studies in animals [3, 4] have been cited as often 
as the six papers focussing on human analyses [5-10] (108 vs. 112) (table 1). Citation has a 
potentiating effect. The more the papers are cited the greater the impression that the 
mentioned data are reliable. Surprisingly, none of the 220 papers citing the sparse literature 
on iodine- / ICM- concentrations in breast milk presented a synopsis as we are in this paper, 
and no author hazarded the opinion that the analysed cohort is much too small for 
recommendations or guidelines. This is indeed surprising, because with respect to other 
papers focussing on ICM-hypersensitivity reactions, for example, the greater the number of 
patients studied the better [12, 13].   
 
Taken together, a detailed search for papers presenting data of ICM concentrations in breast 
milk following ICM-injection leads to the detection of eight publications (75% of papers deal 
with results in humans). Results of twenty-two breast feeding women receiving six different 
ICMs (two non-ionic, and four ionic), are described, so far. Currently, only two of these ICMs 
are EMA- or FDA-approved, and on the market (table 1). Therefore, the problems with these 
six human papers are; the number of analysed breast-feeding women is too small, the 
methods used for detecting contrast media or iodine are heterogenous, and only one non-
ionic ICM (namely iohexol) has been analysed. The published studies differ widely in the 
range of ICM concentrations reported (factor 100: 0.3 up to 36.5 mg iodine per day). This 
means, the existing data are not a suitable basis on which to base guidelines. In other words, 
now the only recommendation is to stop breast-feeding for 24 hours following the injection of 
an iodinated CM. 
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Table 1 – Overview of results published in eight papers. * According to google scholar; ** 
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